Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS (NOVN)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

UK Health Body Approves Novartis's Tasigna For CML

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/25/2012 | 01:16am CET

The U.K.'s health-cost regulator has decided to back an expensive cancer drug from Novartis AG (NVS) for treating chronic myeloid leukemia--but not one from U.S.-based Bristol-Myers Squibb Co. (BMY)--after the Swiss drug maker offered to cut the drug's price.

The independent National Institute for Clinical Excellence, known by its acronym NICE, said Wednesday it approved Novartis's Tasigna and the company's older drug, whose brand name is Glivec, for use in treating CML on the publicly funded National Health Service. The generic names for Tasigna and Glivec are nilotinib and imatinib, respectively.

However, NICE said it wasn't approving Bristol-Myers Squibb's Sprycel, also known as dasatinib.

CML is a cancer of blood-forming cells in the bone marrow that usually develops slowly, which is why it is described as a chronic form of the disease.

NICE director Carole Longson said: "The recommendations reaffirm the use of imatinib as an effective treatment for the majority of patients and a cost-effective use of NHS resources, and we are also very pleased to be able to add a further treatment option for these patients by recommending nilotinib.

"Although no trials directly comparing dasatinib and nilotinib were available, the committee concluded from indirect comparisons that dasatinib and nilotinib could be considered equally as effective in treating CML.

"However, the manufacturer of nilotinib has already agreed with the Department of Health to provide the drug to the NHS at a discounted price. This reduction in cost enabled the independent committee to approve nilotinib for use on the NHS."

Dasatinib and nilotinib both cost over GBP30,000 per patient a year and the standard dose of imatinib costs GBP20,000.

NICE didn't disclose the price discount offered by Novartis for nilotinib.

-By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS
09:18a PFIZER : weighs `strategic options` for newly FDA-approved Remicade biosim, its ..
12:38a NELSON PELTZ : P&G appoints Peltz to board despite losing proxy battle
12:38a PROCTER & GAMBLE : P&G appoints Peltz to board despite losing proxy battle
12/15 NOVARTIS : ACC Urges for Protection of Privilege in Johns Hopkins Univ. V Alcon ..
12/15 NOVARTIS : NAD Recommends Alcon Laboratories Discontinue Certain Claims for 'Cle..
12/15 NOVARTIS : Result of Oncology Ventures Drug Response Prediction for TKI drug fro..
12/15 Germany's Merck in fresh bid to enter U.S. MS pill market
12/15DJNOVARTIS : Oncology CEO Bruno Strigini to Retire
12/15 NOVARTIS : announces Oncology head to retire
12/14 NOVARTIS : initiates study evaluating impact of higher dosing of Cosentyx® in pa..
More news
News from SeekingAlpha
12/15 UPCOMING CONVERSATION WITH AN EXPERT : Highlights In CAR-T
12/15 YOUR DAILY PHARMA SCOOP : Conatus Looks Undervalued, Teva Announces Restructurin..
12/14 Did ASH Just Change The Juno Best In Class Thesis?
12/14 More Positives For Roche, The Core Biotech For The Long Run
12/13 CONATUS : Likely To Dash Ahead Of NASH Data
Financials ($)
Sales 2017 49 174 M
EBIT 2017 11 962 M
Net income 2017 7 505 M
Debt 2017 17 812 M
Yield 2017 3,36%
P/E ratio 2017 24,57
P/E ratio 2018 21,41
EV / Sales 2017 4,87x
EV / Sales 2018 4,66x
Capitalization 222 B
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Average target price 87,4 $
Spread / Average Target 3,3%
EPS Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS13.09%221 731
JOHNSON & JOHNSON24.03%380 546
PFIZER12.81%217 327
ROCHE HOLDING LTD.3.91%211 657
MERCK AND COMPANY-4.86%152 759
AMGEN21.32%126 976